This page lists all known medications that could potentially lead to 'Lumbar radiculopathy' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

PALM SPRINGS, California — A new sodium channel blocker, CNV1014802, reduces neuropathic pain from lumbosacral radiculopathy, a phase 2 trial shows. Patients taking the drug improved by about 1 point ...

BOSTON, December 19, 2024--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from its Phase 2 study of suzetrigine in people with painful ...

The study was performed as part of a multicentre randomised controlled trial on the treatment effect of caudal epidural injections. [19] Eligible patients with suspected chronic lumbar radiculopathy, ...

CNV1014802 showed a statistically significant reduction in pain Well tolerated and effective therapeutic dose without any requirement for dose titration Performance potentially broadens the use in ...

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...

BOSTON-- (BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...